Nuvalent director Shair sells shares worth over $2.3 million
- ByInvesting.com
- •
Nuvalent, Inc. is a clinical-stage biopharmaceutical company, which is focused on creating precisely targeted therapies for patients with cancer. Its lead product candidate, NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. Its second lead product candidate, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second, and third generation ALK inhibitors. The Company’s product candidate also includes NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20, treating brain metastases, and avoiding treatment-limiting adverse events, including due to off-target inhibition of wild-type EGFR.